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Plasma HDL can be classified according to their apolipoprotein content into at least two types of lipoprotein particles: 
lipoproteins containing both apo A-I and apo A-II (LP A-I/A-II) and lipoproteins with apo A-I but without apo A-II 
(LP A-I). LP A-I and LP A-I/A-II were isolated by immuno-affinity chromatography. LP A-I has a higher cholesterol 
content and less protein compared to LP A-I/A-II. The average particle mass of LP A-I is higher (379 kDa) than the 
average particle weight of LP A-I/A-II (269 kDa). The binding of 1251-LP A-I to HepG2 cells at 4” C, as well as the 
uptake of 13H]cholesteryl ether-labelled LP A-I by HepG2 cells at 37’ C, was significantly higher than the binding and 
uptake of LP A-I/A-II. It is likely that both binding and uptake are mediated by apo A-I. Our results do not provide 
evidence in favor of a specific role for apo A-II in the binding and uptake of HDL by HepG2 cells. 
Introduction 
High-density lipoproteins (HDL) play an important 
role in the transport of cholesterol from extrahepatic 
tissues to the liver, a process called reverse cholesterol 
transport. This role of HDL has been reinforced by 
studies in cultured cells, showing that HDL can accept 
cholesterol from cells in a process regulated by their 
cholesterol status [1,2]. The exact mechanism of this 
process is still unknown. Specific lipoprotein receptors 
[2-41, desorption of unesterified cholesterol from the 
plasma membrane followed by diffusion through the 
water phase [5-71 and enzyme activities like lecithin: 
cholesterol acyltransferase (LCAT, EC 2.3.1.43) and 
cholesteryl ester transfer protein (CETP) may play a 
role [8-lo]. Although several investigators have visual- 
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ized a specific binding protein for HDL [ll-151, the 
question remains whether binding and net mass 
cholesterol transport are directly related [6,7]. Mendel 
[16,17] measured a molecular mass of approx. 10 to 16 
kDa for the functional unit of the putative HDL bind- 
ing protein using radiation inactivation, while ligand 
blotting experiments point to a binding protein molecu- 
lar mass ranging from 78 to 110 kDa [ll-151. 
It has been shown that liver and steroidogenic tissues 
are especially active in metabolizing HDL particles. 
Cholesteryl esters from HDL are taken up at a greater 
fractional rate than apo A-I, i.e., cholesteryl esters are 
taken up without parallel uptake of HDL-apo A-I [18- 
201 in a process called selective uptake. 
It is known that plasma HDL consists of a heteroge- 
neous population of lipoprotein particles. The various 
HDL subclasses have different densities, which are used 
for the isolation of HDL, and HDL, by ultracentrifu- 
gation. Within these subfractions, particles with diame- 
ters ranging from 8 to 11 nm can be detected using 
gradient gel electrophoresis [21,22]. After subfractiona- 
tion of HDL in seven or nine subfractions by density 
gradient ultracentrifugation apo A-I and apo A-II were 
abundant in all subfractions [23]. 
Chromatography on specific antibody columns is the 
method of choice for the isolation of HDL particles 
with different apolipoprotein composition [23,24]. HDL 
consists of at least two types of particles: lipoproteins 
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containing both apo A-I and apo A-II (LP A-I/A-II) 
and lipoprotein particles with apo A-I but without apo 
A-II (LP A-I). In the present study we characterized the 
chemical compositions of LP A-I and LP A-I/A-II and 
measured their size by gel filtration. This is the first 
report on the binding and uptake of LP A-I and LP 
A-I/A-II by the human hepatoma cell-line HepG2. 
Materials and Methods 
Anti-apo A-I and anti-apo A-II immuno affinity 
chromatography columns, as well as the antibodies used 
for ELISA of apolipoproteins, were generously provided 
by Prof. J.C. Fruchart and Dr. P. Puchois from the 
Institut Pasteur in Lille (France). 
Blood was collected from healthy, normolipidemic 
volunteers in tubes containing EDTA (final concentra- 
tion 1.5 mg/ml) and cooled on ice immediately. The 
subjects were starved overnight. Plasma was collected 
by centrifugation for 1.5 min at 1500 X g,,, and 4” C. 
All following isolation procedures were performed at 
4 o C. Plasma HDL was obtained by gel filtration of 2 
ml plasma using a Superose 6 column (prep. grade, 
1.6 x 50 cm, Pharmacia, Uppsala, Sweden) as described 
in [25]. The elution buffer consisted of 0.9% NaCl, 
containing 2 mM sodium phosphate (pH 7.4) 5 mM 
EDTA and 0.02% NaN,. Plasma cholesteryl (esters), 
phospholipids and triacylglycerols were eluted with high 
recoveries [25]. The HDL fractions obtained after two 
runs (2 ml of plasma each) were pooled and applied on 
a combination of a Sephadex column (G25 Fine, 1.6 X 
35 cm, Pharmacia, Uppsala, Sweden) directly connected 
with a heparin-Sepharose column (1.3 x 29 cm), and 
eluted with 2 mM sodiumphosphate buffer (pH 7.4). 
containing 0.1% NaN, [26]. No apo E was detectable in 
the HDL fraction obtained after this procedure using 
ELISA as described in [27]. 
The next isolation steps consisted of immuno-affinity 
column chromatography, as described by Barbaras et al. 
[24]. For isolation of the LP A-I/A-II particles, the apo 
E-free HDL fraction was passed through the immuno- 
affinity column with anti-apo A-II (flow 10 ml/h). The 
eluate was controlled for remaining apo A-II using a 
highly sensitive ELISA technique [27]. The resulting apo 
A-II-free HDL was subsequently applied on an anti-apo 
A-l column, which bound ail LP A-I. Both antibody 
columns were washed with 150 ml of 0.9% NaCl con- 
taining 0.1 M sodiumphosphate (pH 7.4) 0.1% EDTA 
and 0.1% NaN,, followed by 30 ml 0.5 M NaCl with 10 
mM sodium phosphate (pH 7.4) to elute non-specifi- 
cally bound material. The HDL-subfractions were eluted 
with 30 ml 3 M sodiumthiocyanate, immediately fol- 
lowed by gel filtration on a Sephadex column (G25 
Coarse, 2.6 X 60 cm, Pharmacia, Uppsala, Sweden). 
Both subfractions were concentrated by pressure dialy- 
sis using YMlO membranes (Amicon, Danvers, MA) 
and dialyzed against 0.9% NaCl with 10 mM sodium 
phosphate (pH 7.4) and 1 mM EDTA. 
Labeling of LP A-l and LP A-I/A-II with “‘I or 
[3HJcholesteryl lino/eyI ether 
The HDL-subfractions were iodinated using the ICI 
method (with Na’“‘1 from Amersham International, 
U.K.), as described previously [28]. Labelling efficiency 
was 52 to 68% and the iodine/protein ratio ranged 
from 0.58 to 0.73. Less than 1% of the radioactivity of 
the preparations was free (non-precipitable with tri- 
chloroacetic acid). 2 224.6% was lipid-associated and 94 
to 97% was protein-bound. 
LP A-I and LP A-I/A-II were labelled with 
[la,2a(n)-‘Hlcholesteryl linoleyl ether (obtained from 
Amersham International, U.K.) by incubation of the 
subfractions with cholesteryl ether containing vesicles in 
the presence of CETP. The assay method and partial 
purification of CETP were described before [29]. LP A-I 
or LP A-I/A-II were incubated for 4 h at 37°C with 
phosphatidylcholine/ cholesteryl ether vesicles (ratio of 
5 : 1, formed by sonication, L-a-phosphatidylcholine P- 
5388 from Sigma, St. Louis, MO. U.S.A.) in the pres- 
ence of 0.01% EDTA and enough purified CETP to give 
the CETP activity level present in human plasma. 1 mM 
IAA was added to inhibit LCAT. The amount of phos- 
phatidylcholine used during the incubations was kept as 
low as 1% of the total HDL-phospholipids. in order to 
prevent changes in the phospholipid content of the 
particles. Lipoproteins and CETP were separated after 
incubation by density gradient ultracentrifugation and 
the HDL-subfractions were reisolated from the density 
range 1.06331.21 g/ml. The specific radioactivity ranged 
from 50 to 80 dpm/ng protein. 
After labelling, the subfractions were dialyzed against 
0.9% NaCl containing 10 mM sodiumphosphate (pH 
7.4) and 1 mM EDTA. If necessary, the fractions were 
dialyzed against the cell culture medium prior to the 
binding experiments. 
Cell culture 
HepG2 cells were cultured in DMEM/FlO’ (1 : 1) 
medium (DMEM was purchased from Flow Laborato- 
ries and FlO+ from Gibco), supplemented with L- 
glutamine, penicilline/streptomycine and 10% FCS, at 
37°C in 95% air and 5% COz. Cells were plated in 
multiwell dishes (35 mm, 0.5-1.0. lo6 cells/well) 3 d 
prior to each experiment. After 2 d the medium was 
removed, cells were rinsed three times with 0.9% NaCl 
containing 10 mM sodiumphosphate (pH 7.4) and new 
medium, containing either 10% FCS or 2% BSA (A-4378, 
Sigma, St. Louis, MO), was added to the wells. After a 
preincubation period of 24 h the cells were ready for use 
in the binding experiments. At that time cells were near 
confluency. 
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After three washes with cold 0.9% NaCl, containing 
10 mM sodium phosphate (pH 7.4) the cells were 
placed on ice and 1 ml test medium was added. The test 
medium used was culture medium (see above) in which 
the FCS was replaced by 2% BSA. The amount of 
iodinated lipoproteins in the test media ranged from 0 
to 20 pg protein/ml. Non-specific binding was mea- 
sured after addition of 100 pg protein/ml of unlabelled 
LP A-I or LP A-I/A-II. This low amount of HDL-pro- 
tein was used for practical reasons. Addition of high 
concentrations (e.g., 1 mg protein/ml) is impractical, 
due to the limited capacity of the antibody columns. 
Therefore, we measured an apparent ‘specific binding’, 
which is somewhat lower than the real specific binding. 
Competition was measured using 5 pg iodinated lipo- 
protein LP A-I or LP A-I/A-II per ml medium with 
O-175 pg/ml unlabelled protein of the competing lipo- 
protein particle. For all experiments the cells were in- 
cubated for 4 h at 4°C under a H,O-saturated atmo- 
sphere with 5% COz and 95% air. After incubation the 
dishes were placed on ice, the medium was removed and 
the cells were washed three times with 0.2% BSA in 
0.9% NaCl with 50 mM Tris-HCl (pH 7.4) to remove 
non-specifically bound material. Then the cells were 
rinsed three times with 0.9% NaCl containing 50 mM 
Tris-HCl (pH 7.4). The cell protein was dissolved in 2 
ml 1 M NaOH. The cell-bound radioactivity was mea- 
sured using a gamma counter, and protein was mea- 
sured according to Lowry et al. [30]. 
The apo A-I and apo A-II concentrations were de- 
termined by immuno-electrophoresis [32]. The molar 
ratio of apo A-I to apo A-II was calculated using a M, 
of 2.8. lo4 and 1.7. lo4 for apo A-I and apo A-II, 
respectively. 
Particle weights of LP A-I and LP A-I/A-II were 
determined by gel filtration on a Aca 34 column 
(Ultrogel, Reactifs IBF, Villeneuve-la-Garenne, France). 
The column was calibrated with reference proteins with 
known molecular masses (gel filtration calibration kits 
No. 17-0441-01 and 17-0445-01, Pharmacia, Uppsala, 
Sweden). The reference proteins were: thyroglobulin 
(M, = 6.69 . 105), ferritine (M, = 4.4. 105), catalase (M, 
= 2.32. 105) and lactate dehydrogenase (M, = 1.40. 
10’). Dextran blue (M, = 2.0 106) was used as a marker 
of the void volume. The resulting K, values were plotted 
against the log M, resulting in a regression line with a 
correlation coefficient of 0.999. 
For statistical analysis the non-parametric Wilcoxon 
test was used [33]. Results were regarded as significantly 
different if P < 0.05. 
Results 
Binding plus uptake of iodinated or [3H]cholesteryl 
ether-labelled LP A-I and LP A-I/A-II were measured 
at 37°C at a concentration of 20 pgg/ml of protein. This 
binding plus uptake will be referred to as total cell 
association. The overall procedure for these experiments 
at 37°C is identical with that described above for the 
experiments at 4°C. 
Table I shows that the two HDL-subfractions, LP 
A-I and LP A-I/A-II, differ in chemical composition. 
LP A-I contains less protein and more cholesterol than 
LP A-I/A-II. The difference in cholesterol content is 
caused mainly by a higher level of unesterified 
cholesterol in LP A-I. Consequently, LP A-I/A-II has a 
higher proportion of esterified cholesterol than LP A-I. 
The molar ratio of esterified cholesterol to unesterified 
cholesterol is 3.0 for LP A-I/A-II and only 1.9 for LP 
A-I. Not only do the chemical compositions of LP A-I 
and LP A-I/A-II differ, also the average particle weights 
are significantly different. The value for LP A-I is 
379 i 62 kDa, (mean & S.D., n = 3) and the value for 
LP A-I/A-II is 269 + 17 kDa (mean f S.D., n = 3) (see 
also Fig. 1). Fig. 1 demonstrates that LP A-I as well as 
LP A-I/A-II consists of particles with a wide range of 
Lipoprotein analyses 
The protein content of the HDL-subfractions was 
measured according to [30]. Total cholesterol, unesteri- 
fied cholesterol, triacylglycerols and phospholipids were 
measured by enzymatic methods. The following kits 
were used: cholesterol, No. 310328 and cholesterol 
esterase (Boehringer Mannheim, F.R.G.); triacyl- 
glycerols, No. 877557 (Boehringer Mannheim, F.R.G.); 
phospholipids, No. 61491 (Bio-Mtrieux, Craponne, 
France). Cholesteryl esters were calculated by difference 
of total and unesterified cholesterol. 
The purity of the isolated HDL-subfractions was 
determined by two different methods: apolipoprotein 
measurements with ELISA techniques [27] and 15% 
SDS-polyacrylamide gel electrophoresis [31]. Autoradio- 
grams were made after electrophoresis of iodinated 
HDL-subfractions. The dried gel was exposed to Hyper- 
film-MP (Amersham International, U.K.) for 3 d at 
TABLE I 
The chemical composition of the human HDL-subclasses LP A-I und LP 
A-I/A-II 
Protein 
Phospholipids 
Total cholesterol 
Unesterified cholesterol 
Cholesteryl esters 
Triacylglycerola 
LP A-I LP A-l/A-II 
55.2k3.0 a 60.3 f 2.4 h 
25.6 + 2.2 23.7 k 2.0 
17.0+1.2 13.9iO.7’ 
6.0i0.X 3.5 kO.1 
11.4k2.1 10.2 + 0.6 
2.9 f 0.4 2.1 kO.1 
’ Values given are weight % (meanfS.D.. n = 6) 
’ Significantly different from LP A-I, P = 0.025. 
’ Idem. P = 0.005. 
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Fig. 1. A typical example of separate gel filtrations of ‘H-cholester- 
ylether labelled LP A-I (O -0) and LP A-I/A-II (o- 0) 
on a Aca 34 column at 4°C. The column was calibrated with the 
following proteins: lactate dehydrogenase (LDH). catalase. ferritin 
and thyroglobulin (Thyroglo). 
diameters. The mean size of LP A-I and LP A-I/A-II 
varies between different individuals, but for each indi- 
vidual LP A-I is always bigger than LP A-I/A-II. The 
cholesteryl ether label and the phospholipids have simi- 
lar size distributions for LP A-I as well as LP A-I/A-II 
(not shown). The gel filtration profile of LP A-I shows 
two peaks (Fig. 1): a main peak that corresponds with a 
HSA 
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Fig. 2. Non-reduced 15% SDS-polyacrylamide gel electrophoreais of 
the HDL-subfractions. Lane 1 HSA marker, lane 2 apo A-I marker, 
lane 3 apo A-II marker, lane 4 apo C-III-I marker, lane 5 LP A-I and 
lane 6 LP A-I/A-II. The gel was stained with Coomassie Brilliant 
Blue. 
start 
apo A-l 
apo A-II 
Fig. 3. Autoradiogram of “‘1-LP A-I (left lane) and LP A-I/A-II 
(right lane) after non-reduced 15% SDS-polyacrylamide gel electro- 
phoresis. 
mean spherical particle radius of 6.2 nm and a smaller 
peak with a radius of approx. 5.2 nm. The profile of LP 
A-I/A-II shows only one peak (Fig. 1) corresponding 
with a mean particle radius of 5.5 nm. 
No apo A-II could be detected in the LP A-I fraction 
on SDS-polyacrylamide gel electrophoresis (Fig. 2). 
There was only a very small amount of contaminating 
protein (co-migrating with HSA) visible in the LP A- 
I/A-II fraction. A minor protein band, migrating 
slightly faster than the main band of apo A-I, was 
present in LP A-I as well as in the pure apo A-I marker. 
The nature of this minor band, which is not present in 
LP A-I/A-II, is presently unknown. It is likely to be a 
I ,’ 
/’ 
/’ 
/I’ 
/’ 
,’ 
/’ 
15 20 
pg LPlml 
Fig. 4. The total (closed symbols) and “specific binding” (open 
symbols) at 4°C of LP A-I (0, O) and LP A-I/A-II (A, A) to HepG2 
cells (ng HDL protein/mg cell protein, values are given as means& 
S.E.M.. n = 3)). 
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TABLE II 
Competition of the binding of iodinated LP A-I and iodinated LP 
A-I/A-II by unlabelled LP A-I/A-II or LP A-I in HepC2 cells at 4°C 
Ligand Competitor Competitor % Labelled 
(5 pg/ml) @g/ml) ligand bound 
‘*‘I-LP A-I LP A-I/A-II 0 100 a (n = 3) 
35 92*16 b (n=3) 
15 65+1 (n=2) 
135 60f4 (n=2) 
175 59fl (n=2) 
‘251-LP A-I/ 
A-II LP A-I 0 100 (n=3) 35 62+6b (n = 3) 
75 5lIl (n=2) 
135 49*5 (n=2) 
175 43*1 (n=2) 
a Values are means (+ S.E.M.). 
’ Significant difference between the % found for LP A-I and LP 
A-I/A-II competition (Wilcoxon’s non-parametric test, P < 0.05). 
degradation product of apo A-I. Evidence in favor of a 
high sensitivity for proteolytic degradation in specific 
HDL subfractions has been published recently [34]. 
ELISA assays showed that the percentage of apo A-II 
in the LP A-I subfraction is less than O.l%, apo C-III 
(quantitatively the most important apo C in HDL) 
ranged from l-3%, and apo E was less than 0.5% of 
total apolipoprotein. The molar ratio of apo A-I/ape 
A-II in the LP A-I/A-II subfraction, measured in de- 
lipidated samples, was 1.4 -t 0.2 (mean * S.E.M., n = 5). 
Fig. 3 shows an autoradiogram obtained after SDS- 
polyacrylamide gel electrophoresis of iodinated LP A-I 
and LP A-I/A-II. Only very little radioactivity is pre- 
sent in proteins other than apo A-I or apo A-II. 
Fig. 4 shows the binding of iodinated LP A-I and LP 
A-I/A-II to HepG2 cells, measured at 4°C. The total 
binding of LP A-I was high compared to the binding of 
LP A-I/A-II. Both HDL-subfractions showed a satura- 
ble ‘specific binding’ of about 50% of the total binding, 
if measured at a lipoprotein concentration of 5 pg/ml. 
TABLE III 
The binding and uptake of the protein and cholestetyl ester moieties of 
LP A-I and LP A-I/A-II by HepG2 cells at 37°C 
“‘I-protein ‘H-lipid Ratio ‘H : ‘25I 
Preincubation of cells in 10% FCS: 
LP A-I 0.36 f 0.02 a 1.24+0.05 a 3.4 
LP A-I/A-II 0.29 f 0.02 b 0.74 + 0.06 b 2.5 
Preincubation of cells in 2% BSA: 
LP A-I 0.34+0.01 0.77 f 0.01 2.3 
LP A-I/A-II 0.29 f 0.01 b 0.54 f 0.03 b 1.9 
a All values are cell-associated radioactivity expressed in % of added 
radioactivity, mean + S.E.M., n = 3). 
’ Significantly different from the value for LP A-I, P < 0.05. 
The construction of accurate Scatchard plots for the 
calculation of binding affinities and maximal binding 
was not possible, due to the limited number of measure- 
ments. Table II shows the competition of LP A-I/A-II 
for i2’I-LP A-I binding and of LP A-I for ‘251-LP 
A-I/A-II binding. Both subfractions are able to dis- 
pj:ce each other, although LP A-I can displace more 
I-LP A-I/A-II, especially at low concentrations. Ta- 
ble III gives the data on total HDL association to 
HepG2 cells at 37°C. The cells were incubated with 20 
pg HDL protein/ml, using different preincubation con- 
ditions. Two differently labelled preparations were used: 
‘251-apolipoprotein label and [ 3H]cholesteryl ether label. 
The results show that the binding of LP A-I is signifi- 
cantly higher than that of LP A-I/A-II. This finding is 
not dependent on the preincubation conditions. The 
cholesteryl ether-derived cell-associated radioactivity 
was higher than that derived from iodinated lipopro- 
teins (expressed as % of the added radioactivity), indi- 
cating a preferential uptake of cholesteryl ether over 
apolipoproteins. This selective uptake occured for both 
LP A-I and LP A-I/A-II. The ratio cholesteryl ether 
uptake/apolipoprotein uptake ranged from 1.9 to 3.4. 
Discussion 
The differences between LP A-I and LP A-I/A-II 
resemble the known differences between HDL, and 
HDL,. Both LP A-I and HDL, have a relatively low 
protein content and a relatively high total cholesterol 
content. The esterification level is highest in LP A-I/A- 
II and HDL,. The observed protein contents of both 
LP A-I and LP A-I/A-II (55 and 60%, respectively) are 
higher than those reported for HDL isolated by ultra- 
centrifugation [35]. HDL, and HDL, contain about 
40% and 53% protein, respectively. The most likely 
explanation for these differences in protein content 
between the two isolation methods is ‘stripping’ of 
HDL-apolipoproteins during ultracentrifugation [36,37]. 
Kunitake et al. [36] showed that 20% of the total apo 
A-I of human HDL was lost after one 24 h ultracentri- 
fugation at high salt concentration. Cheung and Wolf 
[37] found that 14% of the apo A-I of LP A-I was found 
in the d 1 1.21 g/ml fraction after ultracentrifugation. 
About 9% of rat HDL apo A-I is lost during one 
ultracentrifugal step [38,39]. 
The high protein content of LP A-I and LP A-I/A-II 
is a common finding after isolation of HDL-subfrac- 
tions by immuno-affinity column chromatography. Mc- 
Vicar et al. [40] isolated apo A-I containing particles 
with 62-70% protein. Cheung and Wolf [37] isolated LP 
A-I particles with 43356% and LP A-I/A-II particles 
with 55-60% protein. Lower values (34-46% of protein) 
were calculated by summation of the specific apolipo- 
protein concentrations [41]. However, absolute stan- 
dardization of these apolipoprotein assays is difficult 
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and total protein determination will probably result in 
more reliable data.. 
The isolated HDL-subfractions had average particle 
masses of about 380 and 270 kDa for LP A-I and LP 
A-I/A-II, respectively. The particle mass for LP A- 
I/A-II measured by us was higher than the values 
reported for HDL, [42,43]. This again may be caused 
by the avoidance of ultracentrifugation (see above). 
Changes in apo A-I containing particles due to ultra- 
centrifugation were described before [40,44]. Vezina et 
al. [44] showed that apo A-I containing lipoproteins 
may have particle mass up to 815 kDa, if separated by 
gradient gel electrophoresis. After prior ultracentrifuga- 
tion, no apo A-I containing lipoproteins with average 
particle masses above 390 kDa could be detected any- 
more. In another study [40], apo A-I containing par- 
ticles, isolated by immuno-affinity chromatography, also 
had higher mean particle radii than HDL isolated by 
ultracentrifugation. 
The subdivision of LP A-I in two subfractions (see 
Fig. 1) is also evident on gradient gel electrophoresis 
[45,46]. In [45] the main band consisted of lipoproteins 
of approx. 300 kDa and the smaller band was about 164 
kDa. The LP A-I isolated in our study was bigger: the 
major component has a particle weight of approx. 380 
kDa. The mean particle size of LP A-I and LP A-I/A-II 
reported in part of the existing literature is somewhat 
smaller than the values obtained in the present study. 
This may be partly due to the method of analysis: 
measurements by gel filtration give slightly higher val- 
ues for the radii of HDL particles, compared to gradi- 
ent gel electrophoresis [47]. From our data we calcu- 
lated mean particle radii of 6.2 nm for LP A-I and of 
5.5 nm for LP A-I/A-II. Using the same method, i.e., 
gel filtration, Cheung et al. [47] found similar results for 
LP A-I (5.7 to 6.5 nm) and higher values for LP 
A-I/A-II (6.0 to 6.3 nm). Size measurements using the 
electron microscope showed apo A-I containing par- 
ticles with a radius ranging from 5 to 6 nm [40]. 
We find a molar ratio of apo A-I/ape A-II in LP 
A-I/A-II particles of 1.4 f 0.2. From a study of Ohta et 
al. [41] a ratio of 1.5 for women and 1.6 for men can be 
calculated. James et al. [48] measured a ratio of 1.5 + 0.1. 
Cheung and Albers [45] isolated particles with a ratio of 
2 and showed that ultracentrifugation had no effect on 
the apo A-I/ape A-II molar ratio. However, the major 
fraction of the LP A-I/A-II particles they isolate con- 
tains 2 molecules of apo A-I and l-2 molecules of apo 
A-II [49]. In our study at least 3 molecules of apo A-I 
and 2 molecules of apo A-II appear to be present on 
each LP A-I/A-II particle. For LP A-I, 2-4 apo A-I 
molecules per particle were proposed before [50,51]. 
From the data obtained in this study we calculate that 
the average LP A-I particle may contain 7-8 molecules 
of apo A-I. This high number follows from the combi- 
nation of a relatively high protein content as well as 
particle weight of the LP A-I subfraction. Separate gel 
filtration of the two subfractions (Fig. 1) showed that 
both subfractions consisted of particles with greatly 
variable size. This is not caused by an overloading of 
the column. Comparable amounts of protein of the 
calibration standards gave narrow peaks. This implies 
that affinity chromatography is necessary to isolate pure 
LP A-I and LP A-I/A-II, and that gel filtration alone 
or ultracentrifugation alone cannot provide pure sub- 
fractions. 
In all our experiments the binding and uptake of LP 
A-I was higher compared to LP A-I/A-II. For both 
subfractions the specific binding was about 50% of the 
total amount of bound HDL. Other investigators also 
measured a relatively high non-specific binding of HDL 
to HepG2 cells [52]. When the binding of LP A-I/A-II 
is related to the concentration of apo A-I the binding 
curves of LP A-I and LP A-I/A-II do not differ any- 
more (not shown), suggesting that only apo A-I mediates 
the binding. The fact that LP A-I was able to displace 
bound lz51-LP A-I/A-II also supports the role of apo 
A-I in the binding of HDL to its binding site. These 
competition experiments are not interfered with by ex- 
change of labelled apo A-I (on bound iodinated lipo- 
protein) with unlabelled competing apo A-I. This type 
of exchange could cause apparent competition [53]. 
Exchange of apolipoproteins between different particles 
does not occur at 4°C however [54]. 
Whether both apo A-I and apo A-II are ligands for 
the binding of HDL remains controversial. There are 
only two other studies in which LP A-I and LP A-I/A-II 
particles were used in binding experiments. Pig liver, 
adrenal and skeletal muscle membranes [55] also show a 
higher binding of LP A-I compared to LP A-I/A-II. 
Differentiated Ob1771 mouse adipocytes show binding 
of apo A-I, as well as apo A-II-containing liposomes 
[56]. In this study, a striking difference in the function 
of the two HDL-subfractions was found when 
cholesterol efflux from adipocytes was measured 
[24,56,57]. Apo A-II-containing liposomes and LP A- 
I/A-II failed to promote cholesterol efflux, resulting in 
the hypothesis that apo A-II has an antagonistic effect 
on cholesterol efflux. Another study shows that apo 
A-II on HDL inhibits HDL-binding to adipocyte cell 
membranes [58]. HDL,-binding to human adipocyte 
membranes decreased 92% after enrichment of HDL, 
with apo A-II. In our study with HepG2 cells LP A-I 
and LP A-I/A-II were both bound to about the same 
extent and cholesterylether uptake from HDL was com- 
parable. In several studies using ligand blotting, apo A-I 
as well as apo A-II are able to bind to a receptor 
protein in membranes of various cell types, e.g., liver, 
adrenal cortex, kidney, fibroblasts, smooth muscle cells, 
macrophages and adipocytes [13,57,59]. In contrast, 
Schmitz et al. [60] state that only apo A-I is the ligand 
for the HDL receptor, since only anti-apo A-I was able 
to inhibit binding of HDL to peritoneal macrophages. 
Anti-apo A-II, anti-apo E and anti-apo C’s did not 
inhibit HDL-binding. 
A selective uptake of HDL-cholesteryl ether, com- 
pared to HDL-apolipoprotein, was observed in HepG2 
cells, measured at 37°C confirming earlier reports 
[19,61]. In our experiments [3H]cholesteryl ether was 
used as a non-degradable label. Theoretically the ‘251 
label will be released from the cells after degradation of 
the apolipoproteins. However, no degradation could be 
measured during the short incubation periods used in 
our experiments (not shown). The selective uptake was 
higher for LP A-I than it was for LP A-I/A-II, but the 
differences were small. Our results do not support a 
specific role for apo A-II in the uptake of HDL- 
cholesteryl esters. 
The effects of CETP, secreted by HepG2 cells [62], 
could influence our results. However, no CETP activity 
is detectable in the medium after 4 h of incubation (not 
shown). Recently, Rinninger and Pittman [19] showed 
that secreted CETP activity does not influence HDL- 
cholesteryl ether uptake during short incubation peri- 
ods. 
This study describes for the first time the binding 
and uptake of HDL-subfractions, isolated by immuno- 
affinity chromatography, to HepG2 cells. No big dif- 
ferences in the binding or uptake of LP A-I and LP 
A-I/A-II were observed and no specific role of apo 
A-II in HDL-binding or uptake of cholesteryl esters was 
detected. 
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